胰高血糖素样肽-1受体激动剂在儿童患者中的临床应用进展  

Progress on Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists in Children

作　　者：王月玥 卢金淼[1] 朱琳[1] 王艺 李智平[1] WANG Yueyue;LU Jinmiao;ZHU Lin;WANG Yi;LI Zhiping(Dept.of Clinical Pharmacy,National Children’s Medical Center/Children’s Hospital of Fudan University,Shanghai 201102,China;Dept.of Pharmacy,Qidong Branch,Children’s Hospital of Fudan University,Qidong Women’s and Children’s Health,Jiangsu Qidong 226200,China;Dept.of Neurology,National Children’s Medical Center/Children’s Hospital of Fudan University,Shanghai 201102,China)

机构地区：[1]国家儿童医学中心/复旦大学附属儿科医院临床药学部,上海201102 [2]复旦大学附属儿科医院启东分院/启东市妇幼保健院药学部,江苏启东226200 [3]国家儿童医学中心/复旦大学附属儿科医院神经内科,上海201102

出　　处：《中国医院用药评价与分析》2024年第1期119-123,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：中国-世界卫生组织双年合作项目(No.WPCHN1611348)。

摘　　要：胰高血糖素样肽-1受体激动剂(GLP-1RA)在成人2型糖尿病的治疗中已有广泛应用,近年来的研究结果表明,GLP-1RA也可用于儿童肥胖和短肠综合征的治疗。本篇综述主要关注GLP-1RA在儿童患者中的临床应用进展。GLP-1RA通过改善胰岛素敏感性、减轻体重、降低血压和降低代谢综合征发生风险来改善儿童肥胖患者的代谢异常和心血管疾病风险。在短肠综合征中,GLP-1RA可增加肠道对养分的吸收,刺激胰岛素分泌,促进葡萄糖的利用和减少外源性葡萄糖的使用,增加脂肪的利用。GLP-1RA虽在临床应用中具有良好的安全性和耐受性,但也存在低血糖、恶心和呕吐、胰腺炎和甲状腺癌等风险,故需要密切监测患者的不良反应,进一步开展更加系统和深入的研究。Glucagon-like peptide-1 receptor agonists(GLP-1RA)have been widely used in the treatment of adult type 2 diabetes,and recent studies have shown that GLP-1RA can also be used in the treatment of children with obesity and short bowel syndrome.This review focuses on the progress of GLP-1RA in clinical use in children.GLP-1RA improves metabolic abnormalities and cardiovascular disease risk in children with obesity by improving insulin sensitivity,reducing weight,lowering blood pressure,and reducing the risk of developing metabolic syndrome.In short bowel syndrome,GLP-1RA can increase intestinal absorption of nutrients and can stimulate insulin secretion,thereby promoting glucose utilization and reducing exogenous glucose use,increasing fat utilization.Although GLP-1RA are safe and well tolerated in clinical use,there are risks of hypoglycemia,nausea and vomiting,pancreatitis,and thyroid cancer,so it is necessary to closely monitor the adverse drug reactions and to further carry out more systematic and in-depth studies.

关 键 词：胰高血糖素样肽-1受体激动剂 肥胖 儿童 短肠综合征 安全性 

分 类 号：R977.15[医药卫生—药品]